COVID-19: The therapeutic landscape.


Journal

Med (New York, N.Y.)
ISSN: 2666-6340
Titre abrégé: Med
Pays: United States
ID NLM: 101769215

Informations de publication

Date de publication:
14 05 2021
Historique:
pubmed: 27 4 2021
medline: 27 4 2021
entrez: 26 4 2021
Statut: ppublish

Résumé

Therapeutics for hospitalized COVID-19 patients were identified through a robust research response with several lessons learned: clinical trial data should guide therapeutic use, results should not be extrapolated between disease stages, and robust studies should be designed to give clinically relevant data. These lessons should be applied to the outpatient research response.

Identifiants

pubmed: 33899041
doi: 10.1016/j.medj.2021.04.015
pii: S2666-6340(21)00164-1
pmc: PMC8057546
doi:

Types de publication

Journal Article

Langues

eng

Pagination

493-497

Informations de copyright

© 2021 Elsevier Inc.

Déclaration de conflit d'intérêts

Dr. Fauci declares no competing interests. Dr. Paules is the site principal investigator at Penn State Health for The Adaptive Covid-19 Treatment Trial (ACTT), which receives funding from the National Institutes of Health.

Auteurs

Catharine I Paules (CI)

Assistant Professor Infectious Diseases, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA.

Anthony S Fauci (AS)

Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH